Liangming Zhang

Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer

Liangliang Dong, Liming Chen, Weimin Wang et al. · Diagnostic Pathology · 2015 · 46 citations · Full text

Medicine, Cancer Biology, Oncology +16

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial

Yuankai Shi, Jian Fang, Xuezhi Hao et al. · Signal Transduction and Targeted Therapy · 2022 · 34 citations · Full text

Medicine, Oncology, Pharmacology +16

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)

Yuankai Shi, Jianhua Chen, Helong Zhang et al. · BMC Medicine · 2023 · 22 citations · Full text

Medicine, Oncology, Pharmacology +15

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study

Yuankai Shi, Yanzhen Guo, Xingya Li et al. · The Lancet Respiratory Medicine · 2025 · 13 citations

Medicine, Oncology, Pharmacology +15

MiR-942-5p inhibits tumor migration and invasion through targeting CST1 in esophageal squamous cell carcinoma

Liangming Zhang, Sunxing Yu, Xiaoqing Yin et al. · PLoS ONE · 2023 · 12 citations · Full text

Medicine, Molecular Biology, Oncology +17